(December 27, 2023) Natera Inc. succeeded in obtaining a preliminary injunction against NeoGenomics Laboratories, Inc.’s medical assay test. Natera’s ongoing federal lawsuit alleges that NeoGenomics’ ...

NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed ...

In Natera, Inc v. Neogenomics Laboratories, Inc., Appeal No. 24-1324 the Federal Circuit held that preliminary injunction may be valid if a substantial question of invalidity was not raised, even if ...

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...

Genetic testing company Natera sued Neogenomics Laboratories Inc. for patent infringement on Friday in North Carolina Middle District Court. The court case, filed by Quinn Emanuel Urquhart & Sullivan ...

NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic ...

Lab is located in same building as PPD ® Laboratories’ Central Lab and will support Asia-Pacific oncology trials FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc.

Emotional intelligence is increasingly required in today’s workplace. To help students and job candidates meet this demand and flourish professionally, Florida Gulf Coast University (FGCU) and ...

NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...